SecBot SecBot
PRESS-RELEASE ·Filed Sep 4, 2026

RPRX

Royalty Pharma plc
BEARISH
Impact 5/10
Horizondays Processed2mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▼ Bearish

The clinical failure is contained by the protective deal structure, but it removes a potential upside catalyst from the portfolio. Traders should watch for any further pipeline updates or changes to the 2030 receipts target, though the reiteration of the $4.7B+ target provides near-term support.

DirectionBearish
Confidencehigh
Horizondays

SPINRAZA

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and marketed since December 2016; high-dose regimen approved March 2026
Next catalyst
None dated

What to watchWatch SPINRAZA quarterly revenue trends and high-dose regimen adoption as a read on Biogen's legacy cash-flow stability. The drug still pulls in ~$1.5B/year but is declining ~12% YoY, while the newly approved high-dose label could slow erosion. The more impactful catalyst for BIIB stock over the next 12 months is likely LEQEMBI's Alzheimer's rollout and the Apellis acquisition integration, not SPINRAZA.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$60.59
T+0 close · Sep 4, 2026 · via day close
Latest settled
−6.85%
T+20 · $56.44 · next T+60 in 16d
Vs SPY
−8.56%
α at T+20
Latest observation
+16.47%
T+48 · FF3 residual α
  1. T+0 · Sep 8 $60.59entry
  2. T+1 · 2mo ago 0.00%α +0.46% · $60.59
  3. T+5 · 2mo ago −3.50%α −2.38% · $58.47
  4. T+20 · 6w ago −6.85%α −8.56% · $56.44
  5. T+49 · todayOpen
  6. T+60 · in 16d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Royalty Pharma announced that Novartis' Phase 3 HORIZON trial for pelacarsen failed to meet its primary endpoint in atherosclerotic cardiovascular disease. The company's $500 million Ionis funding agreement was structured with $350 million allocated to Spinraza royalties and only $150 million to pelacarsen, and Royalty Pharma expects to recoup its total investment and earn a modest positive return. The company reiterated its 2030 Portfolio Receipts target of $4.7 billion or more, limiting the financial damage from this clinical failure.

Key Financial Metrics

Deal Value
$500.0M

Key Facts

  • Novartis' Phase 3 HORIZON trial for pelacarsen did not meet its primary endpoint in atherosclerotic cardiovascular disease.
  • Royalty Pharma's $500 million Ionis funding agreement allocated $350 million to Spinraza royalties and $150 million to pelacarsen royalties.
  • Royalty Pharma expects to recoup its total investment and earn a modest positive return despite the pelacarsen failure.
  • Royalty Pharma reiterates its 2030 Portfolio Receipts target of $4.7 billion or more.
  • No milestone payments will be made to Ionis following the HORIZON results.

Financial Impact

$150 million of the $500 million Ionis funding was allocated to pelacarsen royalties; the company expects to recoup total investment and earn a modest positive return, with no milestone payments due.

portfolio receiptsinvestment return

Risk Factors

  • Further clinical setbacks in Royalty Pharma's development-stage portfolio could pressure the stock.
  • The pelacarsen failure removes a potential growth driver, limiting upside optionality.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3356846

Track record

22 reports on RPRX

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $68.53 +1.41% ▲ +2.07% −1.22% vs SPY
  2. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $68.53 +1.43% ▲ +3.63% +4.54% vs SPY
  4. Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $68.53 −18.91% ▲ +2.46% +3.77% vs SPY
  5. Sep 4, 202610w ago Press Release Bearish 5/10 Viewing Entry $60.59 to $58.47 Now $68.53 −13.10% ▲ +3.50% +2.38% vs SPY
  6. Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $68.53 +13.14% ▲ +2.24% +1.12% vs SPY
  7. Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $68.53 +17.02% ▲ +3.45% +5.41% vs SPY
  8. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $68.53 +18.66% ▲ +2.55% +2.19% vs SPY
  9. Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $68.53 +18.62% ▲ +0.33% −0.60% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $68.53 +18.62% ▲ +0.33% −0.60% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Tue (17h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 4, 2026